Mapmygenome, Lucid Launch DNA Onco Screen
Originally published in Telangana Today, February 22, 2019.
Hyderabad: Lucid Diagnostics has partnered with MapmyGenome, a molecular diagnostics company, to advance personalised and preventive cancer care by combining genomics and pathology lab services. Lucid will offer DNA Onco Screen to customers and physicians for prevention and early detection of cancers.
The genetic risk assessment will be available for cancers such as colorectal, prostate, lung, breast, bladder, melanoma, renal cell carcinoma, ovarian, thyroid, chronic lymphocytic leukaemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, pancreatic, basal cell carcinoma and testicular cancer.
“By looking at DNA as well as biochemical markers, DNA Onco Screen helps one understand lifetime genetic risks for a wide spectrum of cancers, early detection and roadmap for personalised, precise and preventive cancer management strategy.” — Dr Sunitha Lingareddy, MD, Lucid Diagnostics
MapmyGenome CEO Anu Acharya said: “Combining clinical parameters with genomics will help offer a comprehensive screen. We have spent almost 12–18 months to come out with this test. Lucid has a network of 100 centres and this partnership will improve access to cancer screening.”
DNA Onco Screen will help assess genetic predisposition of individuals to various cancers, physiological traits known to trigger cancer, and lifestyle traits linked to cancer risk. All packages include genetic counselling to help understand individuals’ risk of cancer, inheritance patterns, and lifestyle changes essential to prevent cancer.
Read the original article on Telangana Today →
Know Your Genetic Cancer Risk
Genomepatri by MapmyGenome screens your genetic predisposition to multiple cancers — including breast, colorectal, ovarian, and more. Pair it with a genetic counselling session to understand your results and build a personalised prevention plan.
